

ISSUE DATE February 4, 2015	EFFECTIVE DATE January 21, 2015	NUMBER *See below
SUBJECT Prior Authorization of Botulinum Toxins – Pharmacy Service		BY  Vincent D. Gordon, Deputy Secretary Office of Medical Assistance Programs

PURPOSE:

The purpose of this bulletin is to issue updated handbook pages that include instructions on how to request prior authorization of prescriptions for Botulinum Toxins, including the type of medical information needed to evaluate requests for medical necessity.

SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program and providing services in the fee-for-service (FFS) delivery system, including pharmacy services to residents of long term care facilities.

BACKGROUND:

The Department of Human Services' (Department) Pharmacy and Therapeutics (P&T) Committee meets semi-annually to review published peer-reviewed clinical literature and make recommendations relating to new drugs in therapeutic classes already included in the Preferred Drug List (PDL), changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred, new quantity limits, and classes of drugs to be added to or deleted from the PDL. The P&T Committee also recommends new guidelines or modifications to existing guidelines to evaluate requests for prior authorization of prescriptions for medical necessity.

*01-15-05	09-15-05	27-15-04	
02-15-04	11-15-04	30-15-04	
03-15-04	14-15-04	31-15-05	
08-15-05	24-15-04	32-15-04	33-15-05

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
<http://www.dhs.state.pa.us/provider/healthcaremedicalassistance/index.htm>

DISCUSSION:

The Department is modifying the guidelines to determine medical necessity of Botulinum Toxins for a diagnosis of chronic spasticity resulting from cerebral palsy, multiple sclerosis, traumatic brain injury, spinal cord injury, or stroke based upon a consultation with an independent medical specialist. The updated guidelines to determine medical necessity to reflect this change were subject to public review and comment, and subsequently approved for implementation by the Department. The revised clinical review guidelines to determine the medical necessity of Botulinum Toxins are included in the attached updated provider handbook pages.

PROCEDURE:

The procedures for prescribers to request prior authorization of Botulinum Toxins are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapters related to Botulinum Toxins) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization.

ATTACHMENTS:

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

SECTION II
Botulinum Toxins